FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968654086> ?p ?o ?g. }

• W1968654086 endingPage "1939" @default.
• W1968654086 startingPage "1934" @default.
• W1968654086 abstract "Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in this group, we treated a cohort of lenalidomide refractory patients. Pomalidomide was given orally (2 mg) daily, continuously in 28-day cycles along with dexamethasone (40 mg) given weekly. Responses were assessed by the International Myeloma Working Group Criteria. Thirty-four patients were enrolled. The best response was very good partial response in 3 (9%), partial response (PR) in 8 (23%), best responses (MR) in 5 (15%), stable disease in 12 (35%) and progressive disease in 6 (18%), for an overall response rate of 47%. Of the 14 patients that were considered high risk, 8 (57%) had responses including 4 PR and 4 MR. The median time to response was 2 months and response duration was 9.1 months, respectively. The median overall survival was 13.9 months. Toxicity was primarily hematologic, with grade 3 or 4 toxicity seen in 18 patients (53%) consisting of anemia (12%), thrombocytopenia (9%) and neutropenia (26%). The combination of pomalidomide and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma." @default.
• W1968654086 created "2016-06-24" @default.
• W1968654086 creator A5000308170 @default.
• W1968654086 creator A5001453763 @default.
• W1968654086 creator A5002528975 @default.
• W1968654086 creator A5003015868 @default.
• W1968654086 creator A5007747233 @default.
• W1968654086 creator A5012403700 @default.
• W1968654086 creator A5012884078 @default.
• W1968654086 creator A5012985685 @default.
• W1968654086 creator A5021326343 @default.
• W1968654086 creator A5034160786 @default.
• W1968654086 creator A5036150860 @default.
• W1968654086 creator A5052346975 @default.
• W1968654086 creator A5052783130 @default.
• W1968654086 creator A5054336817 @default.
• W1968654086 creator A5058598134 @default.
• W1968654086 creator A5066940168 @default.
• W1968654086 creator A5069676334 @default.
• W1968654086 creator A5072775789 @default.
• W1968654086 creator A5076611748 @default.
• W1968654086 creator A5083065759 @default.
• W1968654086 creator A5091287816 @default.
• W1968654086 date "2010-09-09" @default.
• W1968654086 modified "2023-10-18" @default.
• W1968654086 title "Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)" @default.
• W1968654086 cites W1798928306 @default.
• W1968654086 cites W1975916512 @default.
• W1968654086 cites W1985147506 @default.
• W1968654086 cites W1992470642 @default.
• W1968654086 cites W2040925557 @default.
• W1968654086 cites W2044436186 @default.
• W1968654086 cites W2048141239 @default.
• W1968654086 cites W2052927123 @default.
• W1968654086 cites W2067161281 @default.
• W1968654086 cites W2095255742 @default.
• W1968654086 cites W2119810076 @default.
• W1968654086 cites W2125559109 @default.
• W1968654086 cites W2142149038 @default.
• W1968654086 doi "https://doi.org/10.1038/leu.2010.190" @default.
• W1968654086 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2978257" @default.
• W1968654086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20827286" @default.
• W1968654086 hasPublicationYear "2010" @default.
• W1968654086 type Work @default.
• W1968654086 sameAs 1968654086 @default.
• W1968654086 citedByCount "182" @default.
• W1968654086 countsByYear W19686540862012 @default.
• W1968654086 countsByYear W19686540862013 @default.
• W1968654086 countsByYear W19686540862014 @default.
• W1968654086 countsByYear W19686540862015 @default.
• W1968654086 countsByYear W19686540862016 @default.
• W1968654086 countsByYear W19686540862017 @default.
• W1968654086 countsByYear W19686540862018 @default.
• W1968654086 countsByYear W19686540862019 @default.
• W1968654086 countsByYear W19686540862020 @default.
• W1968654086 countsByYear W19686540862021 @default.
• W1968654086 countsByYear W19686540862022 @default.
• W1968654086 countsByYear W19686540862023 @default.
• W1968654086 crossrefType "journal-article" @default.
• W1968654086 hasAuthorship W1968654086A5000308170 @default.
• W1968654086 hasAuthorship W1968654086A5001453763 @default.
• W1968654086 hasAuthorship W1968654086A5002528975 @default.
• W1968654086 hasAuthorship W1968654086A5003015868 @default.
• W1968654086 hasAuthorship W1968654086A5007747233 @default.
• W1968654086 hasAuthorship W1968654086A5012403700 @default.
• W1968654086 hasAuthorship W1968654086A5012884078 @default.
• W1968654086 hasAuthorship W1968654086A5012985685 @default.
• W1968654086 hasAuthorship W1968654086A5021326343 @default.
• W1968654086 hasAuthorship W1968654086A5034160786 @default.
• W1968654086 hasAuthorship W1968654086A5036150860 @default.
• W1968654086 hasAuthorship W1968654086A5052346975 @default.
• W1968654086 hasAuthorship W1968654086A5052783130 @default.
• W1968654086 hasAuthorship W1968654086A5054336817 @default.
• W1968654086 hasAuthorship W1968654086A5058598134 @default.
• W1968654086 hasAuthorship W1968654086A5066940168 @default.
• W1968654086 hasAuthorship W1968654086A5069676334 @default.
• W1968654086 hasAuthorship W1968654086A5072775789 @default.
• W1968654086 hasAuthorship W1968654086A5076611748 @default.
• W1968654086 hasAuthorship W1968654086A5083065759 @default.
• W1968654086 hasAuthorship W1968654086A5091287816 @default.
• W1968654086 hasBestOaLocation W19686540861 @default.
• W1968654086 hasConcept C126322002 @default.
• W1968654086 hasConcept C141071460 @default.
• W1968654086 hasConcept C142424586 @default.
• W1968654086 hasConcept C143998085 @default.
• W1968654086 hasConcept C2776063141 @default.
• W1968654086 hasConcept C2776364478 @default.
• W1968654086 hasConcept C2776694085 @default.
• W1968654086 hasConcept C2777063308 @default.
• W1968654086 hasConcept C2778524551 @default.
• W1968654086 hasConcept C2778822529 @default.
• W1968654086 hasConcept C2780401358 @default.
• W1968654086 hasConcept C29730261 @default.
• W1968654086 hasConcept C71924100 @default.
• W1968654086 hasConcept C86803240 @default.
• W1968654086 hasConcept C87355193 @default.
• W1968654086 hasConcept C90924648 @default.
• W1968654086 hasConceptScore W1968654086C126322002 @default.

• next